Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed Non-alcoholic Steatohepatitis (NASH)

NCT06054815 is registered in ClinicalTrials.gov with NeuroBo Pharmaceuticals Inc. as lead sponsor.

NCT NCT06054815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06054815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed Non-alcoholic Steatohepatitis (NASH)
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2023
Completion date
October 30, 2024
Enrollment
109 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis